Patient P-01728

Synthetic patientNBL-101 · Day 119 · 25–34 · M · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 46 SC-12 recommended — Supportive Compound SC-12
Day 47 Patient accepted — Started SC-12 in the companion
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 53 GI symptom burden −16% vs expected — Supportive Compound SC-12
Day 59 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

Toxicity+12
GI instability-5
Inflammatory activity-2
Nutritional resilience+2

What helped?

Supportive Compound SC-12Day 46
Result: symptom burden −16%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 27/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑65
- WearableResting HR 75 bpm
- Wearable2,448 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 66 and rising
- WearableSleep 5.9 h, below personal baseline
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 60
Inflammatory signalling ↓45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 63

DNA

Fictional pharmacogenomic panel

DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.8 · butyrate capacity 27/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 42 ms
Sleep: 6.1 h
Steps: 2,616
Resting HR: 72 bpm

Daily log: GI score 66, nutritional resilience 34, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01615	55%	S14	ME-01	improved	48
P-01656	55%	S14	ME-01	improved	41
P-01582	54%	S14	GI-04	no change	45
P-01605	54%	S14	ME-01	improved	41
P-01612	54%	S14	ME-01	improved	51
P-01830	54%	S14	—	—	44
P-01463	53%	S14	NP-02	no change	41
P-01564	53%	S14	ME-01	improved	39
P-01572	53%	S14	GI-04	worsened	41
P-01841	53%	S14	—	—	48
P-01531	52%	S14	ME-01	improved	51
P-01619	51%	S14	GI-04	worsened	38